ATLANTA, Might 19, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Firm or Virios Therapeutics) is a development-stage biotechnology firm targeted on growing novel anti- Virotherapy to deal with debilitating persistent illnesses together with fibromyalgia (FM) and Lengthy-COVID (LC) at the moment introduced the pricing of its beforehand introduced public providing of 8,500,000 shares of widespread inventory at $0.20 per share. Gross proceeds from the providing are anticipated to be roughly $1.7 million, earlier than deducting placement agent charges and estimated providing bills. The providing is anticipated to shut on Might 22, 2024, topic to customary closing situations. Virios Therapeutics intends to make use of the web proceeds from the proposed providing for preparatory actions to provoke its deliberate Section 2b examine of IMC-2 Lengthy-COVID and for basic company functions.
Maxim Group LLC is performing on an affordable efforts foundation because the unique inserting agent for the proposed providing.
The general public providing is being made pursuant to an efficient shelf registration assertion on Kind S-3 (File No. 333-263700), which was beforehand filed with the Securities and Change Fee (SEC) on March 18, 2022. Declared efficient on April 18, 2022. A preliminary prospectus complement and accompanying prospectus regarding and describing the phrases of the general public providing have been filed with the SEC. The ultimate prospectus complement and prospectus regarding the providing will probably be filed with the SEC and will probably be accessible on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and accompanying prospectus regarding the general public providing may additionally be obtained by contacting Maxim Group LLC, 300 Park Avenue, sixteenth Flooring, New York, NY 10022, Attn: Prospectus Division) or name: (212) 895-3745 or e-mail syndicate@maximgrp.com.
Take away advertisements
.
This press launch doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or different jurisdiction wherein such provide, solicitation or sale can be made. Unlawful earlier than publication.
About Virios Therapeutics, Inc.
Virios Therapeutics (NASDAQ: VIRI) is a development-stage biotechnology firm targeted on advancing novel antiviral therapies to deal with illnesses related to irregular immune responses triggered by viruses, corresponding to fibromyalgia (FM) and COVID-19 ( LC). Hyperactive immune responses related to activation of tissue-resident herpes viruses are considered a possible supply of persistent illnesses corresponding to FM, irritable bowel syndrome, LC, persistent fatigue syndrome, and practical somatic syndromes, all of that are characterised by regression . Our lead growth candidates are novel, proprietary, fixed-dose mixtures of antiviral compounds and celecoxib designed to synergistically inhibit herpesvirus replication with the last word purpose of lowering virus-promoted illness signs. IMC-1, a fixed-dose mixture of famciclovir and celecoxib, has acquired Quick Observe designation from the FDA.
For extra info, please go to www.virios.com.
forward-looking statements
Statements on this press launch comprise forward-looking statements throughout the which means of the U.S. Personal Securities Litigation Reform Act of 1995 which can be topic to substantial dangers and uncertainties. All statements, apart from statements of historic truth, contained on this press launch are forward-looking statements. Ahead-looking statements contained on this press launch may be recognized by means of phrases corresponding to anticipate, imagine, think about, could, estimate, count on, intend, search, could, might, plan, potential, forecast, undertaking, proposal, goal, Goal, ought to, “will,” “would” or the detrimental of those phrases or different related expressions, though not all forward-looking statements comprise these phrases. impacts, dangers and assumptions which can be troublesome to foretell, together with dangers associated to the completion, timing and outcomes of present and future scientific research associated to Virios Therapeutics’ product candidates. Moreover, sure forward-looking statements are based mostly on assumptions about future occasions. and uncertainties are extra absolutely described within the part titled “Danger Elements” in our Amended Annual Report on Kind 10-Okay/A for the 12 months ended December 31, 2023, filed with the Securities and Change Fee. The forward-looking statements contained on this announcement are made as of the date hereof, and Virios Therapeutics, Inc. assumes no obligation to replace such info, besides as required by relevant legislation.
Take away advertisements
.
contact:
IR@Virios.com
